Skip to content
← Full study record

NCT00087698 · FLOW

Participant flow

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma · Source last updated 2009-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)
    id
    FG000
    title
    Pemetrexed
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Lack of Efficacy, Progressive Disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death from Other Causes
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lack of Efficacy, Physician Perception
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Protocol Entry Criteria Not Met
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Clinical Relapse
    8. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death from Study Disease
    9. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death from Study Drug Toxicity
    10. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        77
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        41
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)
    id
    FG000
    title
    Pemetrexed
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Lack of Efficacy, Progressive Disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death from Other Causes
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Withdrawal by Subject
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lack of Efficacy, Physician Perception
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Protocol Entry Criteria Not Met
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Clinical Relapse
    8. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death from Study Disease
    9. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death from Study Drug Toxicity
    10. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        77
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        41
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice